Puma Biotechnology reports Q1 EPS 10c, two estimates 3c

Reports Q1 revenue $43.1M, two estimates $44.5M. “We are pleased to report better than expected net income for the first quarter of 2025,” said Alan H. Auerbach, CEO. “We recently presented new clinical data on neratinib at the American Association for Cancer Research (AACR) Annual Meeting 2025 and we look forward to important updates from our ongoing alisertib clinical studies later this year. We anticipate the following key milestones over the next 12 months: (i) presentation of interim data from ALISCA(TM)-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer (H2 2025); and (ii) presentation of additional interim data from the ALI-4201/ALISCA(TM)-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (H2 2025).”